OCGN
Ocugen
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
consensus rating "Strong Buy"
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About OCGN
Ocugen, Inc.
A clinical-stage biopharmaceutical company that developing therapies to treat the eye diseases
11 Great Valley Parkway, Malvern, Pennsylvania 19355
--
Ocugen, Inc., was incorporated on June 28, 2000 under the federal laws of Massachusetts and conducts its principal business operations in Waltham, Massachusetts. The company is a biotechnology company focused on discovering, developing and commercializing novel gene and cell therapies and vaccines that can improve health and bring hope to patients around the world.
Company Financials
EPS
OCGN has released its 2024 Q4 earnings. EPS was reported at -0.05, versus the expected -0.05, meeting expectations. The chart below visualizes how OCGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OCGN has released its 2024 Q4 earnings report, with revenue of 764.00K, reflecting a YoY change of -45.78%, and net profit of -13.88M, showing a YoY change of -26.53%. The Sankey diagram below clearly presents OCGN’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
